Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX9003 in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX9003 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QPX 9003 (Primary)
  • Indications Acinetobacter infections; Bacterial infections; Gram-negative infections; Pseudomonal infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Qpex Biopharma

Most Recent Events

  • 06 Jul 2023 According to a Brii Biosciences media release, In June 2023, Brii Bio announced definitive agreements with Qpex Biopharma to acquire exclusive global rights of BRII-693 (QPX-9003), expanding its existing rights in Greater China.
  • 17 Oct 2022 According to Brii Biosciences media release, data from this study will be featured in several presentations at the upcoming 2022 ID Week Meeting.
  • 23 Aug 2022 According to a Brii Biosciences media release, the company expects data from study in the fourth quarter of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top